{Reference Type}: Systematic Review
{Title}: Cepacia syndrome in cystic fibrosis: A systematic review of the literature and possible new perspectives in treatment.
{Author}: Daccò V;Alicandro G;Consales A;Rosazza C;Sciarrabba CS;Cariani L;Colombo C;
{Journal}: Pediatr Pulmonol
{Volume}: 58
{Issue}: 5
{Year}: 05 2023 23
{Factor}: 4.09
{DOI}: 10.1002/ppul.26359
{Abstract}: Cepacia syndrome (CS) is an acute, necrotizing pneumonia with a high mortality rate, occurring in patients with cystic fibrosis (CF) infected with Burkholderia cepacia complex (BCC). Due to its low incidence, data on this condition are limited.<BR>We conducted a systematic review of the reported cases of CS by searching MEDLINE, Embase and the Cochrane Library to improve knowledge of this rare but potentially lethal condition.<BR>We included 15 eligible articles, describing 18 cases (9 females) of CS. Median age at onset was 22 years (range: 10-60 years); median time to CS after first infection by BCC was 5 years (range: 1-26 years). Burkholderia cenocepacia was the most frequently reported causative agent. All patients received intravenous antibiotic treatment (most frequently including cotrimoxazole), while inhaled antibiotics were used in five patients (27.8%). Immunosuppressant agents were the most commonly prescribed supportive treatment (n = 7, 38.9%). Half of the patients died (9/18, 50%).<BR>This study describes epidemiological, clinical characteristics, and prognosis of CS cases reported over the last 24 years. CS is a rare yet severe complication of BCC infection in patients with CF, which occurs several years after BCC colonization and has a negative outcome in 50% of the patients. Data are too scanty to identify the most effective therapeutic approach.